July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Metamorphopsia changes after anti-VEGF therapy in branch retinal vein occlusion
Author Affiliations & Notes
  • Kenichiro Mori
    Kyushu University, Fukuoka, Japan
  • Keijiro Ishikawa
    Kyushu University, Fukuoka, Japan
  • Yuki Kubo
    Kyushu University, Fukuoka, Japan
  • Yoshiyuki Kobayashi
    Kyushu University, Fukuoka, Japan
  • Takahito Nakama
    Kyushu University, Fukuoka, Japan
  • Shintaro Nakao
    Kyushu University, Fukuoka, Japan
  • Shigeo Yoshida
    Kurume University, Japan
  • Koh-hei Sonoda
    Kyushu University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Kenichiro Mori, None; Keijiro Ishikawa, None; Yuki Kubo, None; Yoshiyuki Kobayashi, None; Takahito Nakama, None; Shintaro Nakao, Japan (P), KOWASOUYAKU (F); Shigeo Yoshida, None; Koh-hei Sonoda, Japan (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4051. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kenichiro Mori, Keijiro Ishikawa, Yuki Kubo, Yoshiyuki Kobayashi, Takahito Nakama, Shintaro Nakao, Shigeo Yoshida, Koh-hei Sonoda; Metamorphopsia changes after anti-VEGF therapy in branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4051. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We performed a retrospective, observational clinical studyto study changes in amount of metamorphopsia after anti-VEGF therapy for macular edema (ME) in branch retinal vein occlusion (BRVO).

Methods : This study enrolled 29 eyes of 29 patients with ME secondary to BRVO. Those patients were treated with intravitreal injections of anti-VEGF agents using a TAE regimen for at least 18 months at Kyushu University Hospital. We evaluated log MAR visual acuity, central macular thickness(CMT), ME recurrence and amount of metamorphopsia that was quantified by M-CHARTS.

Results : Log MAR visual acuity and CMT significantly improved from 0.35±0.29 and 468±106μm at baseline to 0.06±0.18 and 289±82μm at 18 months (P<0.0001). The average vertical M-CHARTS score significantly decreased from 0.75±0.73 at baseline to 0.59±0.52 and 0.54±0.45 at 1 and 6 months and the horizontal M-CHARTS score significantly decreased from 0.50±0.45 at baseline to 0.35±0.37 at 6 months (p<0.05). However, neither vertical nor horizontal M-CHARTS significantly changed at 18 months (vertical: 0.56±0.58(P=0.10) and horizontal: 0.37±0.44(P=0.12)).ME recurrence occurred in 22 eyes during the follow-up period (75.9%). The number of ME recurrence was significantly smaller in the eyes with maintained or improved vertical M-CHARTS than those with worsened vertical M-CHARTS at 18 months (p<0.05).

Conclusions : Anti-VEGF therapy using TAE regimen may not improve metamorphopsia in BRVO-ME after long-term follow-up.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×